Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine.
Humans
COVID-19
/ immunology
Antibodies, Viral
/ blood
SARS-CoV-2
/ immunology
Male
Female
COVID-19 Vaccines
/ immunology
Adult
Longitudinal Studies
Middle Aged
Immunoglobulin G
/ blood
Antibodies, Neutralizing
/ blood
Cross Reactions
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Adenoviridae
/ immunology
Aged
Cohort Studies
Breakthrough infection
Hybrid immunity
Longevity
SARS-CoV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
03
05
2024
accepted:
05
09
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
Hybrid immunity provides better protection against COVID-19 than vaccination or prior natural infection alone. It induces high magnitude and broadly cross-reactive neutralising anti-Spike IgG antibodies. However, it is not clear how long these potent antibodies last, especially in the context of adenovirus-based COVID-19 vaccines. We conducted a longitudinal cohort study and enrolled 20 adults who had received an adenovirus-based COVID-19 vaccine before a laboratory-confirmed SARS-CoV-2 infection. We followed up the study participants for 390 days post the initial breakthrough infection. We assessed the longevity and cross-reactive breadth of serum antibodies against SARS-CoV-2 variants of concern (VOCs), including Omicron. The binding anti-Spike IgG antibodies remained within the reported putative levels for at least 360 days and were cross-neutralising against Beta, Gamma, Delta, and Omicron. During the follow up period, a median of one SARS-CoV-2 re-infection event was observed across the cohort, but none resulted in severe COVID-19. Moreover, the re-exposure events were associated with augmented anti-Spike and anti-RBD IgG antibody titres. This study confirms that hybrid immunity provides durable broadly cross-reactive antibody immunity against SARS-CoV-2 variants of concern for at least a year (360 days), and that it is further augment by SARS-CoV-2 re-exposure.
Sections du résumé
BACKGROUND
BACKGROUND
Hybrid immunity provides better protection against COVID-19 than vaccination or prior natural infection alone. It induces high magnitude and broadly cross-reactive neutralising anti-Spike IgG antibodies. However, it is not clear how long these potent antibodies last, especially in the context of adenovirus-based COVID-19 vaccines.
METHODS
METHODS
We conducted a longitudinal cohort study and enrolled 20 adults who had received an adenovirus-based COVID-19 vaccine before a laboratory-confirmed SARS-CoV-2 infection. We followed up the study participants for 390 days post the initial breakthrough infection. We assessed the longevity and cross-reactive breadth of serum antibodies against SARS-CoV-2 variants of concern (VOCs), including Omicron.
RESULTS
RESULTS
The binding anti-Spike IgG antibodies remained within the reported putative levels for at least 360 days and were cross-neutralising against Beta, Gamma, Delta, and Omicron. During the follow up period, a median of one SARS-CoV-2 re-infection event was observed across the cohort, but none resulted in severe COVID-19. Moreover, the re-exposure events were associated with augmented anti-Spike and anti-RBD IgG antibody titres.
CONCLUSIONS
CONCLUSIONS
This study confirms that hybrid immunity provides durable broadly cross-reactive antibody immunity against SARS-CoV-2 variants of concern for at least a year (360 days), and that it is further augment by SARS-CoV-2 re-exposure.
Identifiants
pubmed: 39266969
doi: 10.1186/s12879-024-09891-z
pii: 10.1186/s12879-024-09891-z
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Antibodies, Neutralizing
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
959Informations de copyright
© 2024. The Author(s).
Références
COVID-19 Case Tracker [ https://coronavirus.jhu.edu/map.html .].
Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Kent SJ, Triccas JA, Khoury DS, Davenport MP. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52–61.
doi: 10.1016/S2666-5247(21)00267-6
pubmed: 34806056
Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Peacock SJ, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–24.
doi: 10.1038/s41579-021-00573-0
pubmed: 34075212
pmcid: 8167834
Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland W-H, Porrot F, Staropoli I, Lemoine F, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–5.
doi: 10.1038/s41586-021-04389-z
pubmed: 35016199
Goga A, Bekker LG, Garrett N, Reddy T, Yende-Zuma N, Fairall L, Moultrie H, Takalani A, Trivella V, Faesen M, et al. Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa. Lancet. 2022;400(10348):269–71.
doi: 10.1016/S0140-6736(22)01190-4
pubmed: 35809579
pmcid: 9259009
Crotty S. Hybrid immunity. Science. 2021;372(6549):1392–3.
doi: 10.1126/science.abj2258
Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, Al-Khatib HA, Al Thani AA, Coyle P, Al-Kanaani Z, et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMedicine. 2023;95:104734.
doi: 10.1016/j.ebiom.2023.104734
pubmed: 37515986
pmcid: 10404859
Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, Selemon A, Whelan M, Premji Z, Issa H, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556–67.
doi: 10.1016/S1473-3099(22)00801-5
pubmed: 36681084
pmcid: 10014083
Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, Neradilek M, Seydoux E, Jennewein MF, MacCamy AJ, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372(6549):1413–8.
doi: 10.1126/science.abg9175
pubmed: 33766944
pmcid: 8139425
Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, Winders B, Lee JY, Lee DX, Messer WB, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;7(68):eabn8014.
doi: 10.1126/sciimmunol.abn8014
pubmed: 35076258
Andreano E, Paciello I, Piccini G, Manganaro N, Pileri P, Hyseni I, Leonardi M, Pantano E, Abbiento V, Benincasa L, et al. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature. 2021;600(7889):530–5.
doi: 10.1038/s41586-021-04117-7
pubmed: 34670266
pmcid: 8674140
Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:714170.
doi: 10.3389/fimmu.2021.714170
pubmed: 34707602
pmcid: 8542872
Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O’Brien KL, Smith PG, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44.
doi: 10.1016/S0140-6736(22)00152-0
pubmed: 35202601
pmcid: 8863502
Tada T, Zhou H, Samanovic MI, Dcosta BM, Cornelius A, Herati RS, Mulligan MJ, Landau NR. Neutralization of SARS-CoV-2 variants by mRNA and adenoviral vector vaccine-elicited antibodies. Front Immunol. 2022;13:797589.
doi: 10.3389/fimmu.2022.797589
pubmed: 35350781
pmcid: 8957851
Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, Pattekar A, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829.
doi: 10.1126/science.abm0829
pubmed: 34648302
pmcid: 9284784
Suntronwong N, Kanokudom S, Auphimai C, Thongmee T, Assawakosri S, Vichaiwattana P, Yorsaeng R, Duangchinda T, Chantima W, Pakchotanon P, et al. Long-term dynamic changes in hybrid immunity over six months after inactivated and adenoviral vector vaccination in individuals with previous SARS-CoV-2 infection. Vaccines. 2024;12(2):180.
doi: 10.3390/vaccines12020180
pubmed: 38400163
pmcid: 10891631
Medigeshi GR, Batra G, Murugesan DR, Thiruvengadam R, Chattopadhyay S, Das B, Gosain M, Ayushi, Singh J, Anbalagan A, et al. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 infection plus vaccine (hybrid immunity) post 6-months. EBioMedicine. 2022;78:103938.
doi: 10.1016/j.ebiom.2022.103938
pubmed: 35305396
pmcid: 8923830
Anscombe C, Lissauer S, Thole H, Rylance J, Dula D, Menyere M, Kutambe B, van der Veer C, Phiri T, Banda NP, et al. A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study. BMC Infect Dis. 2023;23(1):79.
doi: 10.1186/s12879-022-07941-y
pubmed: 36750921
pmcid: 9902830
Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D, Snipe HD, Brown JS, Workman L, Zar HJ, et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2022;40(2):306–15.
doi: 10.1016/j.vaccine.2021.12.006
pubmed: 34933765
Keeton R, Tincho MB, Suzuki A, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Skelem S, Adriaanse M, et al. Impact of SARS-CoV-2 exposure history on the T cell and IgG response. Cell Rep Med. 2023;4(1):100898.
doi: 10.1016/j.xcrm.2022.100898
pubmed: 36584684
Barnes KG, Levy JI, Gauld J, Rigby J, Kanjerwa O, Uzzell CB, Chilupsya C, Anscombe C, Tomkins-Tinch C, Mbeti O, et al. Utilizing river and wastewater as a SARS-CoV-2 surveillance tool in settings with limited formal sewage systems. Nat Commun. 2023;14(1):7883.
doi: 10.1038/s41467-023-43047-y
pubmed: 38036496
pmcid: 10689440
Dhakal S, Yu T, Yin A, Pisanic N, Demko ZO, Antar AAR, Cox AL, Heaney CD, Manabe YC, Klein SL. Reconsideration of antinucleocapsid IgG antibody as a marker of SARS-CoV-2 infection postvaccination for mild COVID-19 patients. Open Forum Infect Dis. 2023;10(1):ofac677.
doi: 10.1093/ofid/ofac677
pubmed: 36655185
Van Elslande J, Gruwier L, Godderis L, Vermeersch P. Estimated half-life of SARS-CoV-2 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers. Clin Infect Dis. 2021;73(12):2366–8.
doi: 10.1093/cid/ciab219
pubmed: 33693643
Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, Bayer S, Solis M, Laugel E, Reix N, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine. 2021;71:103561.
doi: 10.1016/j.ebiom.2021.103561
pubmed: 34455390
pmcid: 8390300